Dr. Mi-Hua Tao, Professor

Genomics Research Center, Academia Sinica
Phone: 886-2-


1990, Ph.D.¡@Microbiology and Immunology
¡@¡@¡@¡@¡@¡@ Columbia University, USA

1990 - 1993¡@Postdoc Fellow
¡@¡@¡@¡@¡@¡@ Oncology, Stanford University, USA

1993 - 1998¡@Assistant Research Fellow
¡@¡@¡@¡@¡@¡@ Academia Sinica, Taiwan

1998 - 2004¡@Associate Research Fellow
¡@¡@¡@¡@¡@¡@ Academia Sinica, Taiwan

2004 - ¡@¡@¡@Research Fellow
¡@¡@¡@¡@¡@¡@ Academia Sinica, Taiwan


¡@The major interest of our laboratory is to develop novel gene therapy and immunotherapeutic methods to treat cancers and chronic hepatitis B virus infection. We focus on applying cytokines and immune costimulatory molecules to break T cell tolerance commonly found in cancer and chronic hepatitis patients. The state of the art technologies, such as DNA vaccines, dendritic cell vaccines, in vivo electroporation, RNA interference and engineered antibodies are used in these studies. Immunocytokines that can target cytokines to the tumor site have been applied to treat murine and human cancers. Our study shows that intratumoral electroporation of interleukin 12 genes suppressed tumor growth in mice and canine models, and a phase I clinical trial is designed to treat cancer patients. The antitumor and antiviral activities of the two recently discovered interleukin 12 family cytokines, interleukin 23 and interleukin 27, and their effector mechanisms are under investigation. A number of transgenic mouse strains that can produce hepatitis B virus or induce spontaneous hepatocellular carcinoma are generated as animal models to explore novel therapeutic methods, including RNA interference, adoptive T cell transfer-based therapy, and therapeutic vaccines. Details of our current research projects can be found at the web site http://www.ibms.sinica.edu.tw/%7Ebmtao/.


1. Hsu, C. H., Chua, K. Y., Tao, M. H., Lai,Y. L. H., Wu, D., Huang, S. K. & Hsieh, K. H.. ¡§Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization [see comments]¡¨.Nat Med (1996) 2, 540-544.

2. Chow, Y. H., Huang ,W. L., Chi, W. K. , Chu ,Y. D., & Tao, M. H.. ¡§Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.¡¨ J Virol (1997) 71, 169-178.

3. Liu, S. J., Sher, Y. P., Ting, C. C., Liao, K. W., Yu, C. P., & Tao, M. H.. ¡§Treatment of B-cell lymphoma with chimeric IgG and single-chain Fv antibody-interleukin-2 fusion proteins.¡¨ Blood (1998) 92, 2103-2112.

4. Huang, T. H., Wu, P. Y., Lee, C. N., Huang, H. I., Hsieh, S. L., Kung, J., & Tao, M. H. ¡§Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen.¡¨ Blood (2000) 96, 3663-3670 .

5. Lo, C. H., Lee, S. C., Wu, P. Y., Pan, W. Y., Su, J., Cheng, C. W., Roffler, S. R., Chiang, B. L., Lee, C. N., Wu, C. W., & Tao, M. H.. ¡§Antitumor and antimetastatic activity of Interleukin 23. ¡§ J Immunol (2003) 171, 600-607.

Members of Laboratory